Physician profile
Scott A Hebert
NPI 1548603996
$1,763.57
in general payments reported to CMS, 2019-2025
36 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $96.10 · 2022: $146 · 2023: $189 · 2024: $451 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $245.88 | 2019-2025 | |
| Lilly USA, LLC | $143.02 | 2019-2024 | Jaypirca, Verzenio |
| Celgene Corporation | $128.18 | 2022-2025 | Reblozyl, Opdualag |
| US Oncology Corporate, INC. | $117.21 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.91 | 2019 | |
| Daiichi Sankyo INC. | $97.53 | 2019-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $80.87 | 2023-2024 | Brukinsa |
| Amgen INC. | $67.66 | 2019 | |
| Glaxosmithkline, LLC. | $55.71 | 2024-2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $55.69 | 2019-2024 | |
| Pfizer INC. | $54.00 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $45.84 | 2019-2025 | Camzyos |
| Beone Medicines USA, INC. | $41.35 | 2025 | Brukinsa |
| Eisai INC. | $35.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $35.14 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $34.13 | 2019-2020 | |
| Janssen Biotech, INC. | $32.21 | 2022-2023 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $32.10 | 2019 | |
| Genentech USA, INC. | $31.75 | 2019-2025 | Polivy |
| Astrazeneca Pharmaceuticals LP | $30.83 | 2023-2025 | Enhertu |
| Astellas Pharma US INC | $29.58 | 2024 | Xtandi |
| Sobi, INC | $24.86 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $24.09 | 2025 | Sancuso |
| Abiomed | $22.65 | 2024 | Impella |
| Abbvie INC. | $21.84 | 2025 | |
| Inari Medical, INC. | $19.39 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $18.84 | 2025 | Trodelvy |
| Dendreon Pharmaceuticals LLC | $18.36 | 2025 | Provenge |
| Merck Sharp & Dohme LLC | $17.41 | 2019 | |
| Emd Serono, INC. | $16.72 | 2022 | |
| Cti Biopharma Corp. | $16.58 | 2022 | |
| Springworks Therapeutics, INC. | $15.17 | 2025 | Ogsiveo |
| Stemline Therapeutics INC. | $14.17 | 2025 | Orserdu |
| Exelixis INC. | $14.14 | 2019 | |
| Morphosys, US INC. | $13.94 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.